Table 4.
Antibiotic Use in Patients With and Without Stenotrophomonas maltophilia Infection
| Antibiotic | No Infection (n = 82) | Infection (n = 8) |
|---|---|---|
| Cefepime | ||
| Median (IQR) number of days | 3 (0–7) | 2 (0–5) |
| Any use (n, %) | 49 (60) | 4 (50) |
| Cefpodoxime | ||
| Median (IQR) number of days | 0 (0–2) | 0 (0–0) |
| Any use (n, %) | 25 (30) | 1 (13) |
| Ciprofloxacin | ||
| Median (IQR) number of days | 0 (0–2) | 0 (0–2) |
| Any use (n, %) | 24 (30) | 3 (30) |
| Levofloxacin | ||
| Median (IQR) number of days | 5 (0–10) | 0 (0–2) |
| Any use (n, %) | 55 (67) | 3 (38) |
| Linezolid | ||
| Median (IQR) number of days | 6 (2–10) | 8 (4–9) |
| Any use (n, %) | 62 (76) | 8 (100) |
| Meropenem | ||
| Median (IQR) number of days | 2 (0–8) | 5 (3–10) |
| Any use (n, %) | 43 (52) | 7 (88) |
| Piperacillin-tazobactam | ||
| Median (IQR) number of days | 0 (0–2) | 0 (0–3) |
| Any use (n, %) | 23 (28) | 2 (25) |
Abbreviation: IQR, interquartile range.